Shortcut menu
Go to content
Go to footer

Korean

Dong-A ST

  • Dong-A ST

    Dong-A ST - Dong-A ST is leaping forward towards becoming a global pharmaceutical company.

    • Overview
    • CEO’s Message
    • Vision and Values
    • History
    • CI
    • Location

    Dong-A ST menu close

  • Business Areas

    Business Areas- We vow to endeavor to promote human health.

    • Dong-A ST Product
      • Ethical Products
      • Product News
    • Medical Device Business
    • Diagnosis Business
    • Overseas Business
    • License-in
    • License-out
    • Archive

    Business Areas menu close

  • Research and Development

    Research and Development - Our Research Division focuses on the development of global new drugs.

    • Research Division
    • Research Activity
    • Research Achievements
      • Our New Drugs
      • Major Achievements
    • Development stage

    Research and Development menu close

  • CSR

    CSR - We vow to fulfill our corporate social responsibility of creating a bright, warm society.

    • Long March through the National Land
    • Youth Environmental Campaign  Life Love School
    • Golf
    • Other sponsorship programs

    CSR menu colose

  • Investors

    Investment Information - We vow to do our best to reward our shareholders for their strong support.

    • Govornance
      • Shareholderes Meeting
      • Board of Directors
      • Board Committees
      • Audit organization
      • Corporate group
      • Corporate Governance Report
    • Financial Results
    • Stock Information
      • Current price
      • Hourly share price
      • Daily share price
      • Index information
      • Foreigner information
    • Investor Relations
      • Public Notice
      • Presentations
      • Annual Reports
      • IR Inquiry

    Investment Information menu close

  • Newsroom

    Newsroom - Here are the latest news about us, and out latest moves.

    • Newsroom

    Newsroom menu close

  • Contact Us

    Contact Us - Dong-A ST puts its customers first.

    • 1:1 Online Inquiry

    Contact Us menu close

DONG-A ST - We vow to endeavor to promote human health.

Business Areas

  • Dong-A ST Products
    • Ethical Products
    • Product News
    • Healthcare Products
  • Medical Device Business
  • Diagnosis Business
  • Overseas Business
  • License-in
  • License-out
  • Archive

HOME>Business Areas>License-in

License-in

  • License-in

    Dong-A has achieved and maintained the No.1 position in the Korean pharmaceutical industry since 1967 by building competitive marketing capabilities and nation-wide sales networks.

    Leveraging such strong competency in the Korean market, Dong-A has set a new goal to become a global pharmaceutical player and as its first step, we have demerged to the holdings system, of which our parent firm is Dong-A Socio Holdings as of March 2013.

    As a sole subsidiary of Dong-A Socio Holdings in prescription drug market, Dong-A ST is dedicated to developing, manufacturing and distributing ethical drugs while harnessing Dong-A’s value and reputation. Along with in-house developed products, Dong-A has attributed its strong growth to licensed-in products from overseas and domestic partners, where we have valued sustainable and long-term relationships. This is exemplified in our strategic partnership with Meiji Seika, which is dated back to 1959, when we established an antibiotics manufacturing plant and of which our values have continued and recently, set up a new alliance in Biosimilar business.

    Dong-A ST, equipped with a strong track-record in pharmaceutical development and sales, is actively exploring collaboration opportunities in product licensing and other ways of business alliance. For licensing-in, we are seeking novel and innovative treatments for chronic diseases, especially in CNS, CV and Metabolism as a priority target, while maintaining our excellence in the GI and Urology area. We also have a strong interest in licensing value-added products with improved pharmaco-economic profile compared to existing products.

  • Sales

    Sales

    (Unit : 100milion KRW)

    아웃라이센싱 파트너십 표
    Product Active ingredient Indication Category Sales
    2010 2011 2012
    Stillen Eupatilin gastritis In-house 887 881 809
    Lipinon Atorvastatin hyperlipidemia generic 410 460 334
    Plavitor Clopidogrel antithrombosis generic 437 442 314
    Opalmon Limaprost antiplatelet license-in 463 370 244
    Growtropin Somatropin growth hormone in-house 173 211 228
    Talion Bepotastine antihistaminic license-in 196 200 221
    Orodipin Amlodipine high blood pressure generic 289 263 191
    Zydena Udenafil erectile dysfunction in-house 200 203 155
    Motilitone Corydalinco/Pharbitis functional dyspepsia in-house - 5 145
    Glimel Glimepiride diabetes generic 156 154 108
  • Partnership

    Unveiled products

    아발매제품표
    Partner Product Active Ingredient Year
    Almirall Verrumal Soln. Fluorouracil, Salicylic acid 1991
    Optiderm Cream Polidocanol, Urea 1998
    Asahi Kasei Pharma Flivas Tab. Naftopidil 2012
    Aska Pharmaceutical Prostal-L SR Tab. Chlormadinone acetate 1997
    Astellas Pharma Tathion Tab., Inj. L-Glutathione reduced 1970
    Josamycin Tab. Josamycin 1973
    Cefamezin Inj. Cefazolin sodium 1983
    Epocelin Inj. Ceftizoxime sodium 1983
    Perdipine Tab. Nicardipine HCl 1984
        LA Cap 1990
    Gaster Tab., Inj. Famotidine 1986
    Suprax Cap. Cefixime 1989
     Powder 1992
    Rescula Eye Drops Isopropyl unoprosotone 1998
    Gaster D Tab. Famotidine 2001
    Irribow Ramosetron 2010
    GlaxoSmithKline Zovirax Tab. Inj. Eye oint. Cream Acyclovir 1984
    Zofran Tab.Inj. Ondansetron HCl
    dihydrate
    2000
    Zofran ZYDIS Tab. Ondansetron 2000
    Valtrex Tab. Valaciclovir HCl 2000
    iNova Pharmaceuticals Aldara Cream Imiquimod 2002
    Medipost Cartistem Cartilage stem cell 2012
    Meiji Seika Pharma Vistamycin Inj. Ribostamycin sulfate 1976
    ADM Inj. Doxorubicin HCl 1988
    Mitsubishi-
    Tanabe Pharma
    Tanatril Tab. Imidapril HCl 1996
    Talion Tab. Bepotastine besilate 2003
    Eye Drops 2013
    Nippon Kayaku Bleocin Inj. Bleomycin HCl 1971
    Cisplan Inj. Cisplatin 1984
    Lastet Inj. Etoposide 1987
    Lastet-S Cap. 1991
    Ono Pharmaceutical Foy Inj. Gabexate mesylate 1980
    Prostandin Inj. Alprostadil-α-cyclodextrin 1985
    Opalmon Tab. Limaprost 1993
    Onon Cap. Pranlukast hydrate 1998
    Dry Syr. 2001
    Elaspol Sivelestat Na hydrate 2006
    Orion Pharma Fareston Tab. Toremifene citrate 1998
    Sanofi-Pasteur Vaxiflu Inj. Influenza virus A type,Influenza virus B type 1989
    Sigma-Tau Pharmaceuticals Nicetile Tab. Powder Acetyl-L-carnitine HCl 1994
    Toyama Chemical Ozex eye drops Tosufloxacin 2010

    Unveiling products

    Unveiled Products
    Partner Product Active Ingredient Year
    Toyama Chemical Kolbet
    (iguratimod)
    DMARD 2014

    * DMARD: Disease modifying anti-rheumatic drug

    - Last Update 2013.6-

PRIVACY POLICY

  1. Introduction

    This Privacy Policy describes the personally identifiable information that Dong-A ST ("the Company") collects through our Web site located at en.donga-st.com and how we use that information. If you have any questions or comments about this Privacy Policy or our practices regarding your personally identifiable information, please contact us via email or by phone.

  2. Collection of Personal Information

    You can browse our Web site without providing us with any personal information. However, the Company collects your personal information within the scope of its business activities for clearly defined purposes.

  3. Disclosure of Personal Information

    The Company will not disclose, rent, sell or otherwise transfer your personal information without your consent, except as otherwise set out in this Privacy Policy. The Company uses personal information within the limits necessary for the achievement of its objectives.

    The Company may share information provided by our visitors to en.donga-st.com with service providers we have retained to perform services on our behalf. These service providers are contractually restricted from using or disclosing the information except as necessary to perform services on our behalf or to comply with legal requirements. In addition, we may disclose information about you (i) if we are required to do so by law or legal process, (ii) to law enforcement authorities or other government officials, or (iii) when we believe disclosure is necessary or appropriate to prevent physical harm or financial loss or in connection with an investigation of suspected or actual illegal activity.

  4. Changes to this Privacy Policy

    The Company will review this policy in accordance with circumstances and revise it as needed. The revised Privacy Policy will be posted on this Web site. We will treat your personal information in accordance with the Privacy Policy in place at the time of collection of such information, or as you otherwise consent.

팝업 닫기

PRIVACY POLICY

This website is operated by Dong-A ST. All inquiries may be directed to:

Dong-A ST
64 Cheonhodaero, Dongdaemun-gu,
Seoul, Korea

Your use of this website is governed by these terms of use. Please take a few minutes to review these terms when using the Web site.

  1. Copyright Notice

    All of the content you see on this Web site, including, for example, all of images, illustrations, graphics, audio clips, video clips, and text, are subject to trademark, service mark, trade dress, copyright and/or other intellectual property rights or licenses held by Dong-A ST, one of its affiliates or by third parties who have licensed their materials to Dong-A ST. They may therefore not be used without the prior written consent of Dong-A ST for purposes other than to identify and present Dong-A ST’s products and service. The entire content of this Web site is protected under the copyright law of the relevant countries and international treaty. You may download, print and store selected portions of the content, provided you (1) only use these for your own personal, non-commercial use, (2) do not copy or post the content on any network computer or broadcast the content in any media, and (3) do not modify or alter the content in any way, or delete or change any copyright or trademark notice. Any use beyond the provisions outlined above is strictly prohibited

  2. Disclaimer

    While the information on this Web site is given in good faith based upon the latest available to Dong-A ST, no warranty or representation is given concerning such information, which must not be taken as establishing any contractual or other commitment binding upon Dong-A ST or any of its subsidiaries or associated companies.

  3. Changes

    Dong-A ST reserves the right, at its sole discretion, to change, modify, add or remove any portion of this Agreement in whole or in part, at any time. Changes in this Agreement will be effective when notice of such change is posted. Your continued use of the Site after any changes to this Agreement are posted will be considered acceptance of those changes. Dong-A ST may terminate, change, suspend or discontinue any aspect of this Web site, including the availability of any features of the Site, at any time. Dong-A ST may also impose limits on certain features and services or restrict your access to parts or the entire Site without notice or liability.

  4. Linked Sites

    As a convenience to you, we may provide, on this site, links to Web sites operated by other entities. We do not control any of those linked Web sites, we may not have reviewed them, and we make no representations or warranties and assume no responsibility for anything that may happen through your use of any linked Web site. You should read carefully the terms of use of any other Web site that you may use.

팝업 닫기